Journal profile · Pharmacology & Pharmacy
PHARMACOGENOMICS JOURNAL
ISSN 1470-269X · eISSN 1473-1150 · Springer Nature · UNITED STATES · Quarterly · Founded 2001
PHARMACOGENOMICS JOURNAL: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.63; hybrid open access; APC about USD 4,890; median 283 days to acceptance (76 articles, last 24 months); community-reported acceptance: moderate; 34 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
PHARMACOGENOMICS JOURNAL is published by Springer Nature and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms and Genetic Associations and Epidemiology, together about 37.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
The Pharmacogenomics Journal is a print and electronic journal, which is dedicated to the rapid publication of original research on pharmacogenomics and its clinical applications. Key areas of coverage include: Effects of genetic variability on drug toxicity and efficacy Identification and functional characterization of polymorphisms relevant to drug action Integration of new developments in the genome project and proteomics into clinical medicine, pharmacology, and therapeutics Clinical implementation of pharmacogenomics Identification of novel genomic targets for drug development Economics of genome-guided interventions ELSI issues on the clinical implementation of pharmacogenomics Pharmacogenomics in developing countries Companion diagnostics and drug development
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics23.1%
- Drug Transport and Resistance MechanismsMedicine8.8%
- Genetic Associations and EpidemiologyBiochemistry, Genetics and Molecular Biology5.5%
- Pharmacological Effects and Toxicity StudiesMedicine4.6%
- Colorectal Cancer Treatments and StudiesMedicine3.8%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology3.7%
- Computational Drug Discovery MethodsComputer Science3.6%
- Acute Lymphoblastic Leukemia researchMedicine3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedCASCurrent ContentsPublisher website
Other: EBSCO, ProQuest, Portico, Crossref, British Lib, Nature Asia, Chineseacademy, Globalnewsmedia, Infotrieve, Kesli, Ovid, Live Elsevier/Excerpta Medica, Swetsnet, Keystone-gale, University of Toronto
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.63LetPub ·
- Impact factor (publisher) 2025
- 2.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.6Publisher website ·
- CiteScore 2026-06
- 5.7LetPub ·
- SJR 2026-06
- 0.76LetPub ·
- SNIP 2026-06
- 0.85LetPub ·
- h-index
- 78LetPub ·
- h-index
- 111OpenAlex ·
- i10-index
- 1,166OpenAlex ·
- 2-year mean citedness
- 3.81OpenAlex ·
- Self-citation rate
- 3.6%LetPub ·
- Share of gold OA articles
- 28.09%LetPub ·
Volume
- Articles per year
- 33LetPub ·
- Articles per year (publisher)
- 2,025Publisher website ·
- Downloads per year (publisher) 2025
- 383,692Publisher website ·
Articles by year OpenAlex count · 1,581 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 37 | 24 | 17 |
| 2025 | 34 | 12 | 93 |
| 2024 | 39 | 18 | 309 |
| 2023 | 21 | 8 | 156 |
| 2022 | 36 | 24 | 629 |
| 2021 | 58 | 25 | 869 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
283 daysMedian, submission to acceptance · P25–P75 168 days – 358 days
- Acceptance to online
- median 13 days (76 articles)
- Submission to online
- median 300 days
- Sample
- 76 articles with submission and acceptance dates (80 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,890 / EUR 3,890 / GBP 3,090 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 2001
- ISSN
- 1470-269X
- Electronic ISSN
- 1473-1150
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about PHARMACOGENOMICS JOURNAL
What CAS zone is PHARMACOGENOMICS JOURNAL in?
In the 2025 upgraded edition of the CAS Journal Ranking, PHARMACOGENOMICS JOURNAL is in Zone 3 of Medicine, and in Zone 3 of the minor category Genetics & Heredity / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of PHARMACOGENOMICS JOURNAL?
The latest impact factor listed by LetPub is 2.63; CiteScore 5.7, h-index 111.
How long does peer review take at PHARMACOGENOMICS JOURNAL?
Based on the dates recorded on 76 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 283 days (interquartile range 168–358 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index PHARMACOGENOMICS JOURNAL?
According to LetPub and DOAJ records, PHARMACOGENOMICS JOURNAL is indexed in SCIE and Scopus. The journal's website also lists PubMed, CAS and Current Contents; that list has not been checked against each database.
Is PHARMACOGENOMICS JOURNAL open access, and what is the APC?
PHARMACOGENOMICS JOURNAL is a hybrid journal. For open-access publication: APC about USD 4,890.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .